⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771 | 1.00 | — | — | |
| SCHEMBL27649543 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL28192375 | 0.97 | — | — | |
| SCHEMBL9177452 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL27297175 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29268322 | 0.97 | HSP90AA1 (0.43) | — | |
| SCHEMBL28110137 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL28202596 | 0.94 | — | — | |
| Bicarbonate SCHEMBL8533354 | 0.87 | KDM4E (0.52) | — | |
| SCHEMBL7673069 | 0.87 | TDP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | claimed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| US-12471596-B2 | Substituted 6-membered heteroaryl piperidinyl ethanones | PI INDUSTRIES LTD. (IN) | 2025-11-18 | — | — | US | disclosed |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240391904-A1 | DIHYDROPYRIMIDINE BASED COMPOUND, PREPARATION METHOD THEREFOR AND USE OF THEREOF | CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| WO-2024159288-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-08-08 | — | — | WO | disclosed |
| EP-4410785-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-111892601-B | Pyridopyrazolocinnoline compound and preparation method and application thereof | 陕西大美化工科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230031192-A1 | NOVEL SUBSTITUTED 6- MEMBERED HETEROARYL PIPERIDINYL ETHANONES | PI INDUSTRIES LTD. (IN) | 2023-02-02 | — | — | US | disclosed |
| US-11505547-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2022-11-22 | — | — | US | disclosed |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-06 | — | — | US | disclosed |
| CN-114206893-A | (hetero) aryl-methyl-thio-beta-D-galactopyranoside derivatives | 爱杜西亚药品有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3952902-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |